Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer
{{output}}
Introduction: The NIAGARA trial demonstrated improved event-free survival (EFS) with perioperative durvalumab plus gemcitabine-cisplatin (GC) vs. GC alone in muscle-invasive bladder cancer (MIBC). This analysis applied mixture cu... ...